BARDA

Cellerant awarded $36.4M to develop CLT-008 for acute radiation syndrome

Thursday, September 6, 2012 07:48 AM

Cellerant Therapeutics, a biotech developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, has been awarded $36.4 million under an option exercised by the Biomedical Advanced Research and Development Authority (BARDA) in the office of the assistant secretary for preparedness and response of the Department of Health and Human Services, for the advanced development of CLT-008, a first-in-class, allogeneic, cell-based therapy for the treatment of acute radiation syndrome (ARS).

More... »

Emergent BioSolutions secures funding from BARDA for anthrax vaccine

Monday, June 4, 2012 11:33 AM

Emergent BioSolutions of Rockville, Md., has reached an agreement with the Biomedical Advanced Research and Development Authority (BARDA) to conduct a non-interference study to be used to support a post-exposure prophylaxis (PEP) indication for BioThrax, an adsorbed anthrax vaccine.

More... »

Biota and Nabi merge to form Biota Pharmaceuticals

Monday, April 23, 2012 09:36 AM

Biota Holdings, an Australian anti-infective drug development company, and Nabi Biopharmaceuticals of Rockville, Md., have signed a Merger Implementation Agreement to form the combined company Biota Pharmaceuticals, to be headquartered in the U.S.

More... »

AMRI and Biota strike development and manufacturing deal

Wednesday, April 18, 2012 09:44 AM

AMRI, a global contract research and manufacturing organization, was selected by Biota Holdings, an Australian anti-infective drug development company, to further develop and manufacture influenza antiviral CS8958 (laninamivir), a second-generation, long-acting neuraminidase inhibitor.

More... »

Avaxia raises $2.2 million in Series A financing

Friday, November 11, 2011 10:44 AM

Avaxia Biologics, a privately-held biotech company, has completed its first close of $2.2 million of a Series A angel-led financing. Cherrystone Angels of Providence, Rhode Island led the round, with participation from Boston Harbor Angels and other undisclosed individuals. Mr. Robert Manning, the co-Chairman of Cherrystone Angels, will join the Avaxia board.

More... »